Zogenix, Inc. (NASDAQ:ZGNX) Director Roger Hawley sold 63,203 shares of Zogenix stock in a transaction on Monday, December 11th. The stock was sold at an average price of $36.84, for a total value of $2,328,398.52. Following the completion of the sale, the director now directly owns 105,575 shares of the company’s stock, valued at approximately $3,889,383. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.
Roger Hawley also recently made the following trade(s):
- On Friday, December 8th, Roger Hawley sold 11,797 shares of Zogenix stock. The stock was sold at an average price of $37.02, for a total value of $436,724.94.
Zogenix, Inc. (NASDAQ ZGNX) opened at $37.00 on Thursday. The company has a quick ratio of 2.71, a current ratio of 2.71 and a debt-to-equity ratio of 0.23. Zogenix, Inc. has a 52-week low of $7.70 and a 52-week high of $42.60.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Sterling Capital Management LLC purchased a new position in Zogenix during the third quarter valued at $237,000. Cubist Systematic Strategies LLC purchased a new position in shares of Zogenix in the third quarter valued at about $226,000. Point72 Asset Management L.P. purchased a new position in shares of Zogenix in the third quarter valued at about $5,338,000. Highbridge Capital Management LLC purchased a new position in shares of Zogenix in the third quarter valued at about $701,000. Finally, Perceptive Advisors LLC lifted its position in shares of Zogenix by 6.4% in the third quarter. Perceptive Advisors LLC now owns 3,670,357 shares of the company’s stock valued at $128,646,000 after acquiring an additional 222,055 shares in the last quarter. Institutional investors own 73.43% of the company’s stock.
Several analysts recently commented on the company. Mizuho reaffirmed a “buy” rating and issued a $51.00 price objective on shares of Zogenix in a report on Thursday, December 7th. JMP Securities assumed coverage on Zogenix in a research report on Monday, November 27th. They set an “outperform” rating and a $56.00 target price on the stock. Leerink Swann reiterated an “outperform” rating and set a $50.00 target price (up from $20.00) on shares of Zogenix in a research report on Monday, October 2nd. ValuEngine upgraded Zogenix from a “sell” rating to a “hold” rating in a research report on Saturday, September 30th. Finally, Stifel Nicolaus reiterated a “buy” rating and set a $55.00 target price (up from $26.00) on shares of Zogenix in a research report on Friday, September 29th. Three analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. Zogenix has a consensus rating of “Buy” and a consensus target price of $42.67.
COPYRIGHT VIOLATION NOTICE: This report was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this report on another domain, it was copied illegally and republished in violation of US & international trademark and copyright laws. The legal version of this report can be accessed at https://www.dispatchtribunal.com/2017/12/14/zogenix-inc-zgnx-director-sells-2328398-52-in-stock.html.
Zogenix Company Profile
Zogenix, Inc is a pharmaceutical company engaged in developing and commercializing central nervous system (CNS) therapies that address specific clinical needs for people living with orphan and other CNS disorders. Its primary area of therapeutic focus is epilepsy and related seizure disorders. Its lead product candidate, ZX008, is a low-dose fenfluramine for the treatment of seizures associated with Dravet syndrome.
Receive News & Ratings for Zogenix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zogenix and related companies with MarketBeat.com's FREE daily email newsletter.